The Winship Cancer Institute of Emory University (Winship) was awarded a type I Cancer Center Support Grant (CCSG) in April 2009. This application represents the first competitive renewal seeking support for years 4-9. Winship is a research university-based matrix cancer center with a vision to be a transformative leader in integrating cancer research care. The 152 Winship members are actively engaged in one of four research programs: Cancer Genetics and Epigenetics, Cancer Cell Biology, Discovery and Developmental Therapeutics, and Cancer Prevention and Control. Winship's members are supported by five shared resources: Cell Imaging and Microscopy, Cancer Genomics, Biostatistics and Bioinformatics, Cancer Tissue and Pathology, and the Clinical Trials Office. Winship currently occupies more than 482k sq. ft. (sf) of dedicated clinical, research, and shared resource space under the direct control of the Executive Director, Walter J. Curran, Jr. M.D. Dr. Curran assumed this position in Sept. 2009 and under his leadership Winship completed a five-year strategic plan, a full reorganization of the senior leadership and administrative infrastructure, and an expansion of the pilot grant program to reward mentorship, inter-programmatic collaboration, innovation in clinical research, and outstanding junior investigators. Winship's 4 research programs have also undergone full re-evaluation and re-invigoration with the addition of several new program leaders and co-leaders, improved member alignment, more focused scientific themes, and greater program leader participation in cancer center decision-making and governance. Since its initial CCSG application Winship has experienced significant research growth and maturation. Total cancer-related peer-reviewed grant funding has increased 35% to $74.6 million, and NCI funding has increased 21% to $29.5 million. Currently there are 19 federally-supported multi-investigator cancer-relevant grants led by Winship members. Winship has outstanding institutional commitment, with more than $115 million in institutional support over the next five years (more than twice that committed in 2008), with its institutional status at the level of Emory's Schools of Medicine, Public Health, and Nursing. Plans are in place for an additional 57K sf of cancer research space. Patient enrollment in Winship's innovative therapeutic and non-therapeutic trials continues to increase, especially among patients from under-represented minority groups. Winship is well-positioned to leverage its growth and development as an NCI-designated cancer center into fulfilling its vision of transformative cancer research and care.

Public Health Relevance

Winship was awarded a type I CCSG in April 2009. This application represents the first competitive renewal seeking support for years 4-9. Winship is a research university-based matrix cancer center with a vision to be a transformative leader in integrating cancer research care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA138292-06S1
Application #
8791151
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2009-04-07
Project End
2017-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$74,858
Indirect Cost
$21,003
Name
Emory University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Sadigh, Gelareh; Holder, Chad A; Switchenko, Jeffrey M et al. (2018) Is there added value in obtaining cervical spine MRI in the assessment of nontraumatic angiographically negative subarachnoid hemorrhage? A retrospective study and meta-analysis of the literature. J Neurosurg 129:670-676
Allen, Samuel C; Lohani, Minisha; Hendershot, Kristopher A et al. (2018) Patient perspectives on compensation for biospecimen donation. AJOB Empir Bioeth 9:77-81
Cassidy, Richard J; Switchenko, Jeffrey M; Yushak, Melinda L et al. (2018) The importance of surgery in scalp angiosarcomas. Surg Oncol 27:A3-A8
Owonikoko, Taofeek K; Busari, Adeniyi K; Kim, Sungjin et al. (2018) Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. Oncology 95:138-146
Koff, Jean L; Li, Jing-Xia; Zhang, Xinyan et al. (2018) Impact of the posttransplant lymphoproliferative disorder subtype on survival. Cancer 124:2327-2336
Dhere, Vishal; Edelman, Scott; Waller, Edmund K et al. (2018) Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. Leuk Lymphoma 59:837-843
Dennison, Cori; King, Adrian R; Rutledge, Hannah et al. (2018) HPV Vaccine-Related Research, Promotion and Coordination in the State of Georgia: A Systematic Review. J Community Health :
Pillai, Rathi N; Behera, Madhusmita; Owonikoko, Taofeek K et al. (2018) Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer 124:271-277
Steuer, Conor E; Griffith, Christopher C; Nannapaneni, Sreenivas et al. (2018) A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. Mol Cancer Ther 17:710-716
Ivanov, Andrei A; Revennaugh, Brian; Rusnak, Lauren et al. (2018) The OncoPPi Portal: an integrative resource to explore and prioritize protein-protein interactions for cancer target discovery. Bioinformatics 34:1183-1191

Showing the most recent 10 out of 331 publications